CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and secure supply of plasma-derived therapies manufactured in Australia.
“CSL Behring welcomes the opportunity to continue our longstanding commitment to provide plasma-derived therapies to treat people in Australia with serious medical conditions including diseases of the immune system, disorders of blood clotting, or people who have been severely injured”, said General Manager of CSL Behring Australia and New Zealand, Ms Loretta Croker.
“The National Fractionation Agreement for Australia provides the healthcare system access to a secure supply of high-quality plasma-derived therapies for the duration of its nine-year term,” she said.
Under the new Agreement, CSL Behring will continue to supply a comprehensive portfolio of life-saving plasma products manufactured in its advanced manufacturing facility located at Broadmeadows (Victoria).
The source material for plasma-derived therapies is human plasma - the liquid part of blood. The plasma CSL Behring will use for supply under the National Fractionation Agreement for Australia is donated by Australia’s volunteer plasma donors, and collected by the Australian Red Cross Blood Service. Working together, CSL Behring, the National Blood Authority, and the Blood Service ensure that Australians can access a comprehensive range of domestically sourced and manufactured plasma-derived therapies.
The National Fractionation Agreement for Australia will commence on 1 January 2018 and will run for a total of nine years until 31 December 2026, subject to satisfactory performance against key measures and the satisfactory completion of a review against specified criteria to be completed during year five. The new Agreement will replace an existing long-term agreement between the National Blood Authority and CSL Behring that expires on 31 December 2017.
+61 9389 3425
+61 429 609 762